Skip to main content
Top
Published in: Breast Cancer Research 1/2008

Open Access 01-02-2008 | Research article

1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (p,p'-DDE) disrupts the estrogen-androgen balance regulating the growth of hormone-dependent breast cancer cells

Authors: Michel Aubé, Christian Larochelle, Pierre Ayotte

Published in: Breast Cancer Research | Issue 1/2008

Login to get access

Abstract

Introduction

Estrogen and androgen signalling pathways exert opposing influences on the proliferation of mammary epithelial and hormone-dependent breast cancer cells. We previously reported that plasma concentrations of 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (p,p'-DDE), the main metabolite of the insecticide DDT (1,1,1-trichloro-2,2-bis [p-chlorophenyl]ethane) and a potent androgen antagonist, were associated with tumor aggressiveness in women diagnosed with breast cancer. We sought to examine the biological plausibility of this association by testing the effect of p,p'-DDE on the proliferation of CAMA-1 cells, a human breast cancer cell line that expresses the estrogen receptor alpha (ERα) and the androgen receptor (AR), in the presence of physiological concentrations of estrogens and androgens in the cell culture medium.

Methods

The proliferation of CAMA-1 cells was determined in 96-well plates following a 9-day treatment with p,p'-DDE alone (0.1 to 10 μM) or in combination with 17β-estradiol (E2) (100 pM) and dihydrotestosterone (DHT) (100, 500, or 1,000 pM). We also assessed p,p'-DDE-induced modifications in cell cycle entry and the expression of the sex-steroid-dependent genes ESR1, AR, CCND1, and TFF1 (pS2) (mRNA and/or protein).

Results

We found that treatment with p,p'-DDE induced a dose-response increase in the proliferation of CAMA-1 cells when cultivated in the presence of physiological concentrations of estrogens and androgens, but not in the absence of sex steroids in the cell culture medium. A similar effect of p,p'-DDE was noted on the proliferation of MCF7-AR1 cells, an estrogen-responsive cell line that was genetically engineered to overexpress the AR. DHT added together with E2 to the cell culture medium decreased the recruitment of CAMA-1 cells in the S phase and the expression of ESR1 and CCND1 by comparison with cells treated with E2 alone. These androgen-mediated effects were blocked with similar efficacy by p,p'-DDE and the potent antiandrogen hydroxyflutamide.

Conclusion

Our results suggest that p,p'-DDE could increase breast cancer progression by opposing the androgen signalling pathway that inhibits growth in hormone-responsive breast cancer cells. The potential role of environmental antiandrogens in breast carcinogenesis deserves further investigation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001, 37 (Suppl 8): S4-66. 10.1016/S0959-8049(01)00267-2.CrossRefPubMed Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001, 37 (Suppl 8): S4-66. 10.1016/S0959-8049(01)00267-2.CrossRefPubMed
2.
go back to reference Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE: Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 2004, 96: 1856-1865.CrossRefPubMed Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE: Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 2004, 96: 1856-1865.CrossRefPubMed
3.
go back to reference Kurebayashi J, Otsuki T, Kunisue H, Tanaka K, Yamamoto S, Sonoo H: Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin Cancer Res. 2000, 6: 512-518.PubMed Kurebayashi J, Otsuki T, Kunisue H, Tanaka K, Yamamoto S, Sonoo H: Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin Cancer Res. 2000, 6: 512-518.PubMed
4.
go back to reference Khan SA, Rogers MA, Khurana KK, Siddiqui JF: Oestrogen receptor expression in normal breast epithelium. Eur J Cancer. 2000, 36 (Suppl 4): S27-S28. 10.1016/S0959-8049(00)00211-2.CrossRefPubMed Khan SA, Rogers MA, Khurana KK, Siddiqui JF: Oestrogen receptor expression in normal breast epithelium. Eur J Cancer. 2000, 36 (Suppl 4): S27-S28. 10.1016/S0959-8049(00)00211-2.CrossRefPubMed
5.
go back to reference Boyd NF, O'Sullivan B, Campbell JE, Fishell E, Simor I, Cooke G, Germanson T: Mammographic signs as risk factors for breast cancer. Br J Cancer. 1982, 45: 185-193.CrossRefPubMedPubMedCentral Boyd NF, O'Sullivan B, Campbell JE, Fishell E, Simor I, Cooke G, Germanson T: Mammographic signs as risk factors for breast cancer. Br J Cancer. 1982, 45: 185-193.CrossRefPubMedPubMedCentral
6.
go back to reference Wallgren A, Baral E, Glas U, Karnström L, Nordenskiöld B, Theve NO, Silfverswärd C: Adjuvant tamoxifen treatment in postmenopausal patients with operable breast cancer. J Steroid Biochem. 1985, 23: 1161-1162. 10.1016/0022-4731(85)90037-8.CrossRefPubMed Wallgren A, Baral E, Glas U, Karnström L, Nordenskiöld B, Theve NO, Silfverswärd C: Adjuvant tamoxifen treatment in postmenopausal patients with operable breast cancer. J Steroid Biochem. 1985, 23: 1161-1162. 10.1016/0022-4731(85)90037-8.CrossRefPubMed
7.
go back to reference Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998, 90: 1371-1388. 10.1093/jnci/90.18.1371.CrossRefPubMed Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998, 90: 1371-1388. 10.1093/jnci/90.18.1371.CrossRefPubMed
8.
go back to reference Jorgensen M, Vendelbo B, Skakkebaek NE, Leffers H: Assaying estrogenicity by quantitating the expression levels of endogenous estrogen-regulated genes. Environ Health Perspect. 2000, 108: 403-412. 10.2307/3454380.CrossRefPubMedPubMedCentral Jorgensen M, Vendelbo B, Skakkebaek NE, Leffers H: Assaying estrogenicity by quantitating the expression levels of endogenous estrogen-regulated genes. Environ Health Perspect. 2000, 108: 403-412. 10.2307/3454380.CrossRefPubMedPubMedCentral
9.
go back to reference Diel P, Olff S, Schmidt S, Michna H: Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol. 2002, 80: 61-70. 10.1016/S0960-0760(01)00173-X.CrossRefPubMed Diel P, Olff S, Schmidt S, Michna H: Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol. 2002, 80: 61-70. 10.1016/S0960-0760(01)00173-X.CrossRefPubMed
10.
go back to reference López-Cervantes M, Torres-Sánchez L, Tobías A, López-Carrillo L: Dichlorodiphenyldichloroethane burden and breast cancer risk: a meta-analysis of the epidemiologic evidence. Environ Health Perspect. 2004, 112: 207-214.CrossRefPubMedPubMedCentral López-Cervantes M, Torres-Sánchez L, Tobías A, López-Carrillo L: Dichlorodiphenyldichloroethane burden and breast cancer risk: a meta-analysis of the epidemiologic evidence. Environ Health Perspect. 2004, 112: 207-214.CrossRefPubMedPubMedCentral
11.
go back to reference Mendez MA, Arab L: Organochlorine compounds and breast cancer risk. Pure Appl Chem. 2003, 75: 1973-2015. 10.1351/pac200375111973.CrossRef Mendez MA, Arab L: Organochlorine compounds and breast cancer risk. Pure Appl Chem. 2003, 75: 1973-2015. 10.1351/pac200375111973.CrossRef
12.
go back to reference Kelce WR, Stone CR, Laws SC, Gray LE, Kemppainen JA, Wilson EM: Persistent DDT metabolite p,p'-DDE is a potent androgen receptor antagonist. Nature. 1995, 375: 581-585. 10.1038/375581a0.CrossRefPubMed Kelce WR, Stone CR, Laws SC, Gray LE, Kemppainen JA, Wilson EM: Persistent DDT metabolite p,p'-DDE is a potent androgen receptor antagonist. Nature. 1995, 375: 581-585. 10.1038/375581a0.CrossRefPubMed
13.
go back to reference Wilson VS, Lambright C, Ostby J, Gray LE: In vitro and in vivo effects of 17beta-trenbolone: a feedlot effluent contaminant. Toxicol Sci. 2002, 70: 202-211. 10.1093/toxsci/70.2.202.CrossRefPubMed Wilson VS, Lambright C, Ostby J, Gray LE: In vitro and in vivo effects of 17beta-trenbolone: a feedlot effluent contaminant. Toxicol Sci. 2002, 70: 202-211. 10.1093/toxsci/70.2.202.CrossRefPubMed
14.
go back to reference Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA: Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J. 2000, 14: 1725-1730. 10.1096/fj.99-0863com.CrossRefPubMed Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA: Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J. 2000, 14: 1725-1730. 10.1096/fj.99-0863com.CrossRefPubMed
15.
go back to reference Dimitrakakis C, Zhou J, Wang J, Belanger A, LaBrie F, Cheng C, Powell D, Bondy C: A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause. 2003, 10: 292-298. 10.1097/01.GME.0000055522.67459.89.CrossRefPubMed Dimitrakakis C, Zhou J, Wang J, Belanger A, LaBrie F, Cheng C, Powell D, Bondy C: A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause. 2003, 10: 292-298. 10.1097/01.GME.0000055522.67459.89.CrossRefPubMed
16.
go back to reference Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD: Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol. 1995, 52: 459-467. 10.1016/0960-0760(95)00005-K.CrossRefPubMed Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD: Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol. 1995, 52: 459-467. 10.1016/0960-0760(95)00005-K.CrossRefPubMed
17.
go back to reference Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T, Rabe T: Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol. 2002, 16: 113-120. 10.1080/713603030.CrossRefPubMed Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T, Rabe T: Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol. 2002, 16: 113-120. 10.1080/713603030.CrossRefPubMed
18.
go back to reference Tormey DC, Lippman ME, Edwards BK, Cassidy JG: Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med. 1983, 98: 139-144.CrossRefPubMed Tormey DC, Lippman ME, Edwards BK, Cassidy JG: Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med. 1983, 98: 139-144.CrossRefPubMed
19.
go back to reference Colleoni M, Coates A, Pagani O, Goldhirsch A: Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: still a question?. Cancer Treat Rev. 1998, 24: 15-26. 10.1016/S0305-7372(98)90068-8.CrossRefPubMed Colleoni M, Coates A, Pagani O, Goldhirsch A: Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: still a question?. Cancer Treat Rev. 1998, 24: 15-26. 10.1016/S0305-7372(98)90068-8.CrossRefPubMed
20.
go back to reference Guttes S, Failing K, Neumann K, Kleinstein J, Georgii S, Brunn H: Chlororganic pesticides and polychlorinated biphenyls in breast tissue of women with benign and malignant breast disease. Arch Environ Contam Toxicol. 1998, 35: 140-147. 10.1007/s002449900361.CrossRefPubMed Guttes S, Failing K, Neumann K, Kleinstein J, Georgii S, Brunn H: Chlororganic pesticides and polychlorinated biphenyls in breast tissue of women with benign and malignant breast disease. Arch Environ Contam Toxicol. 1998, 35: 140-147. 10.1007/s002449900361.CrossRefPubMed
21.
go back to reference Demers A, Ayotte P, Brisson J, Dodin S, Robert J, Dewailly E: Risk and aggressiveness of breast cancer in relation to plasma organochlorine concentrations. Cancer Epidemiol Biomarkers Prev. 2000, 9: 161-166.PubMed Demers A, Ayotte P, Brisson J, Dodin S, Robert J, Dewailly E: Risk and aggressiveness of breast cancer in relation to plasma organochlorine concentrations. Cancer Epidemiol Biomarkers Prev. 2000, 9: 161-166.PubMed
22.
go back to reference Lapointe J, Labrie C: Role of the cyclin-dependent kinase inhibitor p27(Kip1) in androgen-induced inhibition of CAMA-1 breast cancer cell proliferation. Endocrinology. 2001, 142: 4331-4338. 10.1210/en.142.10.4331.CrossRefPubMed Lapointe J, Labrie C: Role of the cyclin-dependent kinase inhibitor p27(Kip1) in androgen-induced inhibition of CAMA-1 breast cancer cell proliferation. Endocrinology. 2001, 142: 4331-4338. 10.1210/en.142.10.4331.CrossRefPubMed
23.
go back to reference Leung BS, Potter AH: Mode of estrogen action on cell proliferative kinetics in CAMA-1 cells. I. Effect of serum and estrogen. Cancer Invest. 1987, 5: 187-194. 10.3109/07357908709011735.CrossRefPubMed Leung BS, Potter AH: Mode of estrogen action on cell proliferative kinetics in CAMA-1 cells. I. Effect of serum and estrogen. Cancer Invest. 1987, 5: 187-194. 10.3109/07357908709011735.CrossRefPubMed
24.
go back to reference Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjöld M, Gustafsson JA: Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 1997, 82: 4258-4265. 10.1210/jc.82.12.4258.PubMed Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjöld M, Gustafsson JA: Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 1997, 82: 4258-4265. 10.1210/jc.82.12.4258.PubMed
25.
go back to reference Lipman ML, Stevens AC, Bleackley RC, Helderman JH, McCune TR, Harmon WE, Shapiro ME, Rosen S, Strom TB: The strong correlation of cytotoxic T lymphocyte-specific serine protease gene transcripts with renal allograft rejection. Transplantation. 1992, 53: 73-79. 10.1097/00007890-199201000-00014.CrossRefPubMed Lipman ML, Stevens AC, Bleackley RC, Helderman JH, McCune TR, Harmon WE, Shapiro ME, Rosen S, Strom TB: The strong correlation of cytotoxic T lymphocyte-specific serine protease gene transcripts with renal allograft rejection. Transplantation. 1992, 53: 73-79. 10.1097/00007890-199201000-00014.CrossRefPubMed
26.
go back to reference Willey JC, Crawford EL, Jackson CM, Weaver DA, Hoban JC, Khuder SA, DeMuth JP: Expression measurement of many genes simultaneously by quantitative RT-PCR using standardized mixtures of competitive templates. Am J Respir Cell Mol Biol. 1998, 19: 6-17.CrossRefPubMed Willey JC, Crawford EL, Jackson CM, Weaver DA, Hoban JC, Khuder SA, DeMuth JP: Expression measurement of many genes simultaneously by quantitative RT-PCR using standardized mixtures of competitive templates. Am J Respir Cell Mol Biol. 1998, 19: 6-17.CrossRefPubMed
27.
go back to reference Ito K, Suzuki T, Akahira J, Moriya T, Kaneko C, Utsunomiya H, Yaegashi N, Okamura K, Sasano H: Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders. Int J Cancer. 2002, 99: 652-657. 10.1002/ijc.10394.CrossRefPubMed Ito K, Suzuki T, Akahira J, Moriya T, Kaneko C, Utsunomiya H, Yaegashi N, Okamura K, Sasano H: Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders. Int J Cancer. 2002, 99: 652-657. 10.1002/ijc.10394.CrossRefPubMed
28.
go back to reference Gillesby BE, Zacharewski TR: pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers. Breast Cancer Res Treat. 1999, 56: 253-265. 10.1023/A:1006215310169.CrossRefPubMed Gillesby BE, Zacharewski TR: pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers. Breast Cancer Res Treat. 1999, 56: 253-265. 10.1023/A:1006215310169.CrossRefPubMed
29.
go back to reference Liao J, Xu X, Wargovich MJ: Direct reprobing with anti-beta-actin antibody as an internal control for western blotting analysis. Biotechniques. 2000, 28: 216-218.PubMed Liao J, Xu X, Wargovich MJ: Direct reprobing with anti-beta-actin antibody as an internal control for western blotting analysis. Biotechniques. 2000, 28: 216-218.PubMed
30.
go back to reference Szelei J, Jimenez J, Soto AM, Luizzi MF, Sonnenschein C: Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology. 1997, 138: 1406-1412. 10.1210/en.138.4.1406.CrossRefPubMed Szelei J, Jimenez J, Soto AM, Luizzi MF, Sonnenschein C: Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology. 1997, 138: 1406-1412. 10.1210/en.138.4.1406.CrossRefPubMed
31.
go back to reference Andersen HR, Andersson AM, Arnold SF, Autrup H, Barfoed M, Beresford NA, Bjerregaard P, Christiansen LB, Gissel B, Hummel R, Jørgensen EB, Korsgaard B, Le Guevel R, Leffers H, McLachlan J, Møller A, Nielsen JB, Olea N, Oles-Karasko A, Pakdel F, Pedersen KL, Perez P, Skakkeboek NE, Sonnenschein C, Soto AM, et al: Comparison of short-term estrogenicity tests for identification of hormone-disrupting chemicals. Environ Health Perspect. 1999, 107 (Suppl 1): 89-108. 10.2307/3434476.CrossRefPubMedPubMedCentral Andersen HR, Andersson AM, Arnold SF, Autrup H, Barfoed M, Beresford NA, Bjerregaard P, Christiansen LB, Gissel B, Hummel R, Jørgensen EB, Korsgaard B, Le Guevel R, Leffers H, McLachlan J, Møller A, Nielsen JB, Olea N, Oles-Karasko A, Pakdel F, Pedersen KL, Perez P, Skakkeboek NE, Sonnenschein C, Soto AM, et al: Comparison of short-term estrogenicity tests for identification of hormone-disrupting chemicals. Environ Health Perspect. 1999, 107 (Suppl 1): 89-108. 10.2307/3434476.CrossRefPubMedPubMedCentral
32.
go back to reference Payne J, Jones C, Lakhani S, Kortenkamp A: Improving the reproducibility of the MCF-7 cell proliferation assay for the detection of xenoestrogens. Sci Total Environ. 2000, 248: 51-62. 10.1016/S0048-9697(99)00479-9.CrossRefPubMed Payne J, Jones C, Lakhani S, Kortenkamp A: Improving the reproducibility of the MCF-7 cell proliferation assay for the detection of xenoestrogens. Sci Total Environ. 2000, 248: 51-62. 10.1016/S0048-9697(99)00479-9.CrossRefPubMed
33.
go back to reference Rasmussen TH, Nielsen F, Andersen HR, Nielsen JB, Weihe P, Grandjean P: Assessment of xenoestrogenic exposure by a biomarker approach: application of the E-Screen bioassay to determine estrogenic response of serum extracts. Environ Health. 2003, 2: 12-10.1186/1476-069X-2-12.CrossRefPubMedPubMedCentral Rasmussen TH, Nielsen F, Andersen HR, Nielsen JB, Weihe P, Grandjean P: Assessment of xenoestrogenic exposure by a biomarker approach: application of the E-Screen bioassay to determine estrogenic response of serum extracts. Environ Health. 2003, 2: 12-10.1186/1476-069X-2-12.CrossRefPubMedPubMedCentral
34.
go back to reference Sohoni P, Sumpter JP: Several environmental oestrogens are also anti-androgens. J Endocrinol. 1998, 158: 327-339. 10.1677/joe.0.1580327.CrossRefPubMed Sohoni P, Sumpter JP: Several environmental oestrogens are also anti-androgens. J Endocrinol. 1998, 158: 327-339. 10.1677/joe.0.1580327.CrossRefPubMed
35.
go back to reference Zwijsen RM, Klompmaker R, Wientjens EB, Kristel PM, van der BB, Michalides RJ: Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. Mol Cell Biol. 1996, 16: 2554-2560.CrossRefPubMedPubMedCentral Zwijsen RM, Klompmaker R, Wientjens EB, Kristel PM, van der BB, Michalides RJ: Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. Mol Cell Biol. 1996, 16: 2554-2560.CrossRefPubMedPubMedCentral
36.
go back to reference Lukas J, Bartkova J, Bartek J: Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol. 1996, 16: 6917-6925.CrossRefPubMedPubMedCentral Lukas J, Bartkova J, Bartek J: Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol. 1996, 16: 6917-6925.CrossRefPubMedPubMedCentral
37.
go back to reference Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994, 369: 669-671. 10.1038/369669a0.CrossRefPubMed Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994, 369: 669-671. 10.1038/369669a0.CrossRefPubMed
38.
go back to reference Zhang SY, Caamano J, Cooper F, Guo X, Klein-Szanto AJ: Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol. 1994, 102: 695-698.CrossRefPubMed Zhang SY, Caamano J, Cooper F, Guo X, Klein-Szanto AJ: Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol. 1994, 102: 695-698.CrossRefPubMed
39.
go back to reference Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer. 1994, 57: 353-361. 10.1002/ijc.2910570311.CrossRefPubMed Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer. 1994, 57: 353-361. 10.1002/ijc.2910570311.CrossRefPubMed
40.
go back to reference Planas-Silva MD, Shang Y, Donaher JL, Brown M, Weinberg RA: AIB1 enhances estrogen-dependent induction of cyclin D1 expression. Cancer Res. 2001, 61: 3858-3862.PubMed Planas-Silva MD, Shang Y, Donaher JL, Brown M, Weinberg RA: AIB1 enhances estrogen-dependent induction of cyclin D1 expression. Cancer Res. 2001, 61: 3858-3862.PubMed
41.
go back to reference Cicatiello L, Addeo R, Sasso A, Altucci L, Petrizzi VB, Borgo R, Cancemi M, Caporali S, Caristi S, Scafoglio C, Teti D, Bresciani F, Perillo B, Weisz A: Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol. 2004, 24: 7260-7274. 10.1128/MCB.24.16.7260-7274.2004.CrossRefPubMedPubMedCentral Cicatiello L, Addeo R, Sasso A, Altucci L, Petrizzi VB, Borgo R, Cancemi M, Caporali S, Caristi S, Scafoglio C, Teti D, Bresciani F, Perillo B, Weisz A: Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol. 2004, 24: 7260-7274. 10.1128/MCB.24.16.7260-7274.2004.CrossRefPubMedPubMedCentral
42.
go back to reference Eeckhoute J, Carroll JS, Geistlinger TR, Torres-Arzayus MI, Brown M: A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev. 2006, 20: 2513-2526. 10.1101/gad.1446006.CrossRefPubMedPubMedCentral Eeckhoute J, Carroll JS, Geistlinger TR, Torres-Arzayus MI, Brown M: A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev. 2006, 20: 2513-2526. 10.1101/gad.1446006.CrossRefPubMedPubMedCentral
43.
go back to reference Poulin R, Simard J, Labrie C, Petitclerc L, Dumont M, Lagace L, Labrie F: Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. Endocrinology. 1989, 125: 392-399.CrossRefPubMed Poulin R, Simard J, Labrie C, Petitclerc L, Dumont M, Lagace L, Labrie F: Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. Endocrinology. 1989, 125: 392-399.CrossRefPubMed
44.
go back to reference Valley CC, Métivier R, Solodin NM, Fowler AM, Mashek MT, Hill L, Alarid ET: Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor alpha N terminus. Mol Cell Biol. 2005, 25: 5417-5428. 10.1128/MCB.25.13.5417-5428.2005.CrossRefPubMedPubMedCentral Valley CC, Métivier R, Solodin NM, Fowler AM, Mashek MT, Hill L, Alarid ET: Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor alpha N terminus. Mol Cell Biol. 2005, 25: 5417-5428. 10.1128/MCB.25.13.5417-5428.2005.CrossRefPubMedPubMedCentral
45.
go back to reference Fan M, Nakshatri H, Nephew KP: Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. Mol Endocrinol. 2004, 18: 2603-2615. 10.1210/me.2004-0164.CrossRefPubMed Fan M, Nakshatri H, Nephew KP: Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. Mol Endocrinol. 2004, 18: 2603-2615. 10.1210/me.2004-0164.CrossRefPubMed
46.
go back to reference Petrel TA, Brueggemeier RW: Increased proteasome-dependent degradation of estrogen receptor-alpha by TGF-beta1 in breast cancer cell lines. J Cell Biochem. 2003, 88: 181-190. 10.1002/jcb.10353.CrossRefPubMedPubMedCentral Petrel TA, Brueggemeier RW: Increased proteasome-dependent degradation of estrogen receptor-alpha by TGF-beta1 in breast cancer cell lines. J Cell Biochem. 2003, 88: 181-190. 10.1002/jcb.10353.CrossRefPubMedPubMedCentral
47.
go back to reference Lonard DM, Nawaz Z, Smith CL, O'Malley BW: The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell. 2000, 5: 939-948. 10.1016/S1097-2765(00)80259-2.CrossRefPubMed Lonard DM, Nawaz Z, Smith CL, O'Malley BW: The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell. 2000, 5: 939-948. 10.1016/S1097-2765(00)80259-2.CrossRefPubMed
48.
go back to reference Wormke M, Stoner M, Saville B, Safe S: Crosstalk between estrogen receptor alpha and the aryl hydrocarbon receptor in breast cancer cells involves unidirectional activation of proteasomes. FEBS Lett. 2000, 478: 109-112. 10.1016/S0014-5793(00)01830-5.CrossRefPubMed Wormke M, Stoner M, Saville B, Safe S: Crosstalk between estrogen receptor alpha and the aryl hydrocarbon receptor in breast cancer cells involves unidirectional activation of proteasomes. FEBS Lett. 2000, 478: 109-112. 10.1016/S0014-5793(00)01830-5.CrossRefPubMed
49.
go back to reference Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW: Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA. 1999, 96: 1858-1862. 10.1073/pnas.96.5.1858.CrossRefPubMedPubMedCentral Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW: Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA. 1999, 96: 1858-1862. 10.1073/pnas.96.5.1858.CrossRefPubMedPubMedCentral
50.
go back to reference Alarid ET, Bakopoulos N, Solodin N: Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol Endocrinol. 1999, 13: 1522-1534. 10.1210/me.13.9.1522.CrossRefPubMed Alarid ET, Bakopoulos N, Solodin N: Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol Endocrinol. 1999, 13: 1522-1534. 10.1210/me.13.9.1522.CrossRefPubMed
51.
go back to reference Andò S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML, Lanzino M: Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol. 2002, 193: 121-128. 10.1016/S0303-7207(02)00105-3.CrossRefPubMed Andò S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML, Lanzino M: Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol. 2002, 193: 121-128. 10.1016/S0303-7207(02)00105-3.CrossRefPubMed
52.
go back to reference Lanzino M, De Amicis F, McPhaul MJ, Marsico S, Panno ML, Andò S: Endogenous coactivator ARA70 interacts with estrogen receptor alpha (ERalpha) and modulates the functional ERalpha/androgen receptor interplay in MCF-7 cells. J Biol Chem. 2005, 280: 20421-20430. 10.1074/jbc.M413576200.CrossRefPubMed Lanzino M, De Amicis F, McPhaul MJ, Marsico S, Panno ML, Andò S: Endogenous coactivator ARA70 interacts with estrogen receptor alpha (ERalpha) and modulates the functional ERalpha/androgen receptor interplay in MCF-7 cells. J Biol Chem. 2005, 280: 20421-20430. 10.1074/jbc.M413576200.CrossRefPubMed
53.
go back to reference Yeh S, Chang C: Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA. 1996, 93: 5517-5521. 10.1073/pnas.93.11.5517.CrossRefPubMedPubMedCentral Yeh S, Chang C: Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA. 1996, 93: 5517-5521. 10.1073/pnas.93.11.5517.CrossRefPubMedPubMedCentral
54.
go back to reference Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP: Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol. 1999, 188: 237-244. 10.1002/(SICI)1096-9896(199907)188:3<237::AID-PATH343>3.0.CO;2-8.CrossRefPubMed Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP: Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol. 1999, 188: 237-244. 10.1002/(SICI)1096-9896(199907)188:3<237::AID-PATH343>3.0.CO;2-8.CrossRefPubMed
55.
go back to reference Clarke RB: Human breast cell proliferation and its relationship to steroid receptor expression. Climacteric. 2004, 7: 129-137. 10.1080/13697130410001713751.CrossRefPubMed Clarke RB: Human breast cell proliferation and its relationship to steroid receptor expression. Climacteric. 2004, 7: 129-137. 10.1080/13697130410001713751.CrossRefPubMed
56.
go back to reference Birrell SN, Butler LM, Harris JM, Buchanan G, Tilley WD: Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J. 2007, 21: 2285-2293. 10.1096/fj.06-7518com.CrossRefPubMed Birrell SN, Butler LM, Harris JM, Buchanan G, Tilley WD: Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J. 2007, 21: 2285-2293. 10.1096/fj.06-7518com.CrossRefPubMed
57.
go back to reference Prest SJ, May FE, Westley BR: The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J. 2002, 16: 592-594.PubMed Prest SJ, May FE, Westley BR: The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J. 2002, 16: 592-594.PubMed
58.
go back to reference Luqmani YA, Campbell T, Soomro S, Shousha S, Rio MC, Coombes RC: Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. Br J Cancer. 1993, 67: 749-753.CrossRefPubMedPubMedCentral Luqmani YA, Campbell T, Soomro S, Shousha S, Rio MC, Coombes RC: Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. Br J Cancer. 1993, 67: 749-753.CrossRefPubMedPubMedCentral
59.
go back to reference Lackey BR, Gray SL, Henricks DM: Crosstalk and considerations in endocrine disruptor research. Med Hypotheses. 2001, 56: 644-647. 10.1054/mehy.2000.1249.CrossRefPubMed Lackey BR, Gray SL, Henricks DM: Crosstalk and considerations in endocrine disruptor research. Med Hypotheses. 2001, 56: 644-647. 10.1054/mehy.2000.1249.CrossRefPubMed
Metadata
Title
1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (p,p'-DDE) disrupts the estrogen-androgen balance regulating the growth of hormone-dependent breast cancer cells
Authors
Michel Aubé
Christian Larochelle
Pierre Ayotte
Publication date
01-02-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1862

Other articles of this Issue 1/2008

Breast Cancer Research 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine